Dan Chan

655 total citations
13 papers, 532 citations indexed

About

Dan Chan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dan Chan has authored 13 papers receiving a total of 532 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Dan Chan's work include Lung Cancer Treatments and Mutations (8 papers), HER2/EGFR in Cancer Research (4 papers) and Histone Deacetylase Inhibitors Research (2 papers). Dan Chan is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), HER2/EGFR in Cancer Research (4 papers) and Histone Deacetylase Inhibitors Research (2 papers). Dan Chan collaborates with scholars based in United States, China and Singapore. Dan Chan's co-authors include Paul A. Bunn, David Raben, Barbara A. Helfrich, Barbara Frederick, Di Zheng, Christopher D. Coldren, Gary L. Johnson, Yayi He, Caicun Zhou and Robert F. Ozols and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Pharmacology and Oncotarget.

In The Last Decade

Dan Chan

13 papers receiving 512 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dan Chan United States 6 287 250 194 84 55 13 532
Arpita Desai United States 10 165 0.6× 229 0.9× 185 1.0× 116 1.4× 62 1.1× 38 451
M. Koukourakis Greece 12 227 0.8× 284 1.1× 125 0.6× 125 1.5× 22 0.4× 28 563
Mariangela Zanghì Italy 7 234 0.8× 144 0.6× 211 1.1× 79 0.9× 29 0.5× 12 414
Caterina Aversa Italy 12 285 1.0× 210 0.8× 222 1.1× 108 1.3× 14 0.3× 32 553
Victoria Rimkunas United States 10 272 0.9× 276 1.1× 225 1.2× 108 1.3× 13 0.2× 26 556
Nicoletta Chicchinelli Italy 9 184 0.6× 184 0.7× 156 0.8× 192 2.3× 37 0.7× 12 453
Lihong Yin United States 11 126 0.4× 259 1.0× 116 0.6× 81 1.0× 52 0.9× 17 405
Annalisa Chiriatti Italy 11 303 1.1× 294 1.2× 81 0.4× 110 1.3× 20 0.4× 13 542
Mohamed Shehata Egypt 12 231 0.8× 195 0.8× 122 0.6× 57 0.7× 14 0.3× 31 458
Lucia Trandafir Switzerland 11 247 0.9× 280 1.1× 272 1.4× 85 1.0× 10 0.2× 22 634

Countries citing papers authored by Dan Chan

Since Specialization
Citations

This map shows the geographic impact of Dan Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Chan more than expected).

Fields of papers citing papers by Dan Chan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Chan. The network helps show where Dan Chan may publish in the future.

Co-authorship network of co-authors of Dan Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Chan. A scholar is included among the top collaborators of Dan Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Chan. Dan Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Chan, Dan. (2021). P76.87 Efficacy of Dacomitinib in EGFR TKI Refractory Metastatic Non-Small Cell Lung Cancer (EGFR Mutant) with Leptomeningeal Metastases. Journal of Thoracic Oncology. 16(3). S627–S627. 3 indexed citations
2.
He, Yayi, Haoyue Guo, Li Diao, et al.. (2021). Prediction of Driver Gene Matching in Lung Cancer NOG/PDX Models Based on Artificial Intelligence. Engineering. 15. 102–114. 4 indexed citations
3.
Yu, Hui, Yayi He, Christopher J. Rivard, et al.. (2016). PS01.20: Immune Checkpoints Expression in Small Cell Lung Cancer Lines. Journal of Thoracic Oncology. 11(11). S281–S281. 1 indexed citations
4.
He, Yayi, Paul A. Bunn, Caicun Zhou, & Dan Chan. (2016). KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer. Oncotarget. 7(50). 82104–82111. 27 indexed citations
5.
He, Yayi, Yan Wang, Theresa A. Boyle, et al.. (2016). Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. Medical Science Monitor. 22. 276–283. 20 indexed citations
6.
Witta, Samir E., Dan Chan, Luc Girard, et al.. (2012). Effects of entinostat onresistance to cetuximab and EGFR TKIs in non-small cell lung cancer.. Journal of Clinical Oncology. 30(15_suppl). e18077–e18077. 2 indexed citations
7.
Yan, Chao, Biehuoy Shieh, Philip Reigan, et al.. (2009). Potent Activity of Indolequinones against Human Pancreatic Cancer: Identification of Thioredoxin Reductase as a Potential Target. Molecular Pharmacology. 76(1). 173–182. 42 indexed citations
8.
Bast, Robert C., Molly Brewer, Changping Zou, et al.. (2007). Prevention and Early Detection of Ovarian Cancer: Mission Impossible?. Recent results in cancer research. 174. 91–100. 85 indexed citations
9.
Frederick, Barbara, Barbara A. Helfrich, Christopher D. Coldren, et al.. (2007). Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma. Molecular Cancer Therapeutics. 6(6). 1683–1691. 224 indexed citations
10.
Chan, Dan, et al.. (2006). Studies of pemetrexed and gemcitabine, alone and in combinations, in human lung cancer models. Journal of Clinical Oncology. 24(18_suppl). 17114–17114. 4 indexed citations
11.
Witta, Samir E., B. Helfrich, Dan Chan, et al.. (2005). Overcoming resistance to EGFR inhibitors in NSCLC cell lines by sequential treatment with histone deacetylase inhibitors. Journal of Clinical Oncology. 23(16_suppl). 7083–7083. 2 indexed citations
12.
Raben, David, Barbara A. Helfrich, Dan Chan, Gary L. Johnson, & Paul A. Bunn. (2002). ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non–small cell lung cancer. Seminars in Oncology. 29(1). 37–46. 116 indexed citations
13.
Chan, Dan, et al.. (1995). Using solenoid valves for proportional pilot pressure control in miniexcavators. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arpita Desai Breakdown of academic impact, for papers by M. Koukourakis Breakdown of academic impact, for papers by Mariangela Zanghì Breakdown of academic impact, for papers by Caterina Aversa Breakdown of academic impact, for papers by Victoria Rimkunas Breakdown of academic impact, for papers by Nicoletta Chicchinelli Breakdown of academic impact, for papers by Lihong Yin Breakdown of academic impact, for papers by Annalisa Chiriatti Breakdown of academic impact, for papers by Mohamed Shehata Breakdown of academic impact, for papers by Lucia Trandafir
Rankless by CCL
2026